Skip to main content
Erschienen in: Quality of Life Research 8/2017

29.03.2017

Visual function quality of life measure changes upon conversion to neovascular age-related macular degeneration in second eyes

verfasst von: Yannis M. Paulus, Joan L. Jefferys, Barbara S. Hawkins, Adrienne W. Scott

Erschienen in: Quality of Life Research | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To determine changes in quality of life measures when choroidal neovascularization (CNV) developed in the second eye of patients with initially unilateral neovascular age-related macular degeneration (AMD).

Methods

We analyzed responses to the 39-item National Eye Institute Visual Function Questionnaire (NEI-VFQ), 36-item Short Form Health Survey (SF-36), and Hospital Anxiety and Depression Scale (HADS) at baseline, and prior to and following second eye CNV diagnosis in 92 participants enrolled in two Submacular Surgery Trials. Paired t-tests for sample sizes over 30 and Wilcoxon signed-rank tests for sample sizes <30 were performed to compare scores.

Results

CNV development resulted in statistically and clinically significant changes in responses to 20 of 39 NEI-VFQ items, indicating visual function decline during a mean interval of 25 months. Little difference was noted between baseline scores and prior to CNV diagnosis, which averaged 8.9 months duration. Subscales demonstrated a statistically significant decline in general vision, near activities, distance activities, social functioning, role difficulties, dependency, and driving. There were minimal changes in the HADS and SF-36 scales.

Conclusion

CNV development in the second eye had a dramatic effect on visual functioning based on patient responses to the NEI-VFQ questionnaire. Our investigation is believed to be the first study using data collected prospectively to demonstrate vision-related quality of life changes that resulted from development of CNV in AMD patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Wong, W. L., Su, X., Li, X., Chueng, C. C. M., Klein, R., Cheng, C. Y., et al. (2014). Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. The Lancet Global Health, 2(2), e106–e116.CrossRefPubMed Wong, W. L., Su, X., Li, X., Chueng, C. C. M., Klein, R., Cheng, C. Y., et al. (2014). Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. The Lancet Global Health, 2(2), e106–e116.CrossRefPubMed
2.
Zurück zum Zitat Friedman, D. S., O’Colmain, B. J., Muñoz, B., Tomany, S. C., McCarty, C., de Jong, P. T., et al. (2004). Prevalence of age-related macular degeneration in the United States. Archives of Ophthalmology, 122(4), 564–572.CrossRefPubMed Friedman, D. S., O’Colmain, B. J., Muñoz, B., Tomany, S. C., McCarty, C., de Jong, P. T., et al. (2004). Prevalence of age-related macular degeneration in the United States. Archives of Ophthalmology, 122(4), 564–572.CrossRefPubMed
3.
Zurück zum Zitat Klein, R., & Klein, B.E. (2013). The prevalence of age-related eye diseases and visual impairment in aging: current estimates. Investigative Ophthalmology & Visual Science, 54(14), ORSF5–ORSF13.CrossRef Klein, R., & Klein, B.E. (2013). The prevalence of age-related eye diseases and visual impairment in aging: current estimates. Investigative Ophthalmology & Visual Science, 54(14), ORSF5–ORSF13.CrossRef
4.
Zurück zum Zitat Rudnicka, A. R., Kapetanakis, V. V., Jarrar, Z., Wathern, A. K., Wormald, R., Fletcher, A. E., et al. (2015). Incidence of late-stage age-related macular degeneration in American whites: Systematic review and meta-analysis. American Journal of Ophthalmology, 160(1), 85–93.e3.CrossRefPubMed Rudnicka, A. R., Kapetanakis, V. V., Jarrar, Z., Wathern, A. K., Wormald, R., Fletcher, A. E., et al. (2015). Incidence of late-stage age-related macular degeneration in American whites: Systematic review and meta-analysis. American Journal of Ophthalmology, 160(1), 85–93.e3.CrossRefPubMed
5.
Zurück zum Zitat Bressler, N. M. (2004). Age-related macular degeneration is the leading cause of blindness. Journal of the American Medical Association, 291(15), 1900–1901.CrossRefPubMed Bressler, N. M. (2004). Age-related macular degeneration is the leading cause of blindness. Journal of the American Medical Association, 291(15), 1900–1901.CrossRefPubMed
6.
Zurück zum Zitat Boyer, D. S., Antoszyk, A. N., Awh, C. C., Bhisitkul, R. B., Shapiro, H., Acharya, N. R., MARINA Study Group, et al. (2007). Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology, 114(2), 246–252.CrossRefPubMed Boyer, D. S., Antoszyk, A. N., Awh, C. C., Bhisitkul, R. B., Shapiro, H., Acharya, N. R., MARINA Study Group, et al. (2007). Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology, 114(2), 246–252.CrossRefPubMed
7.
Zurück zum Zitat Rein, D. B., Wittenborn, J. S., Zhang, X., Honeycutt, A. A., Lesesne, S. B., Saaddine, J., et al. (2009). Vision Health Cost-Effectiveness Study Group. Forecasting age-related macular degeneration through the year 2050: The potential impact of new treatments. Archives of Ophthalmology, 127(4), 533–540.CrossRefPubMed Rein, D. B., Wittenborn, J. S., Zhang, X., Honeycutt, A. A., Lesesne, S. B., Saaddine, J., et al. (2009). Vision Health Cost-Effectiveness Study Group. Forecasting age-related macular degeneration through the year 2050: The potential impact of new treatments. Archives of Ophthalmology, 127(4), 533–540.CrossRefPubMed
8.
Zurück zum Zitat Buckle, M., Lee, A., Mohamed, Q., Fletcher, E., Sallam, A., Healy, R., et al. (2015). Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United Kingdom. Eye (London), 29(3), 403–408.CrossRef Buckle, M., Lee, A., Mohamed, Q., Fletcher, E., Sallam, A., Healy, R., et al. (2015). Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United Kingdom. Eye (London), 29(3), 403–408.CrossRef
9.
Zurück zum Zitat Complications of Age-Related Macular Degeneration Prevention Trial Research Group (2006). Laser treatment in patients with bilateral large drusen: The complications of age-related macular degeneration prevention trial. Ophthalmology, 113(11), 1974–1986.CrossRef Complications of Age-Related Macular Degeneration Prevention Trial Research Group (2006). Laser treatment in patients with bilateral large drusen: The complications of age-related macular degeneration prevention trial. Ophthalmology, 113(11), 1974–1986.CrossRef
10.
Zurück zum Zitat Ying, G. S., Huang, J., Maguire, M. G., Jaffe, G. J., Grunwald, J. E., Toth, C., Comparison of Age-Related Macular Degeneration Treatments Trials Research Group, et al. (2013). Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology, 120(1), 122–129.CrossRefPubMed Ying, G. S., Huang, J., Maguire, M. G., Jaffe, G. J., Grunwald, J. E., Toth, C., Comparison of Age-Related Macular Degeneration Treatments Trials Research Group, et al. (2013). Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology, 120(1), 122–129.CrossRefPubMed
11.
Zurück zum Zitat Singer, M. A., Awh, C. C., Sadda, S., Freeman, W. R., Antoszyk, A. N., Wong, P., et al. (2012). HORIZON: An open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology, 119(6), 1175–1183.CrossRefPubMed Singer, M. A., Awh, C. C., Sadda, S., Freeman, W. R., Antoszyk, A. N., Wong, P., et al. (2012). HORIZON: An open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology, 119(6), 1175–1183.CrossRefPubMed
12.
Zurück zum Zitat Schalnus, R., Meyer, C. H., Kuhli-Hattenbach, C., & Luchtenberg, M. (2010). Time between symptom onset and assessment in age related macular degeneration with subfoveal choroidal neovascularization. Ophthalmologica. Journal international d’ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 224(3), 176–182.CrossRefPubMed Schalnus, R., Meyer, C. H., Kuhli-Hattenbach, C., & Luchtenberg, M. (2010). Time between symptom onset and assessment in age related macular degeneration with subfoveal choroidal neovascularization. Ophthalmologica. Journal international d’ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 224(3), 176–182.CrossRefPubMed
13.
Zurück zum Zitat Oliver-Fernandez, A., Bakal, J., Segal, S., Shah, G. K., Dugar, A., & Sharma, S. (2005). Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. Canadian Journal of Ophthalmology, 40(3), 313–319.CrossRefPubMed Oliver-Fernandez, A., Bakal, J., Segal, S., Shah, G. K., Dugar, A., & Sharma, S. (2005). Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. Canadian Journal of Ophthalmology, 40(3), 313–319.CrossRefPubMed
14.
Zurück zum Zitat Algvere, P. V., Steén, B., Seregard, S., & Kvanta, A. (2008). A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmologica, 86(5), 482–489.CrossRefPubMed Algvere, P. V., Steén, B., Seregard, S., & Kvanta, A. (2008). A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmologica, 86(5), 482–489.CrossRefPubMed
15.
Zurück zum Zitat Liu, T.Y.A., Shah, A. R., & Del Priore, L. V. (2013). Progression of lesion size in untreated eyes with exudative age-related macular degeneration: A meta-analysis using Lineweaver-Burk plots. JAMA Ophthalmology, 131(3), 335–340.CrossRefPubMed Liu, T.Y.A., Shah, A. R., & Del Priore, L. V. (2013). Progression of lesion size in untreated eyes with exudative age-related macular degeneration: A meta-analysis using Lineweaver-Burk plots. JAMA Ophthalmology, 131(3), 335–340.CrossRefPubMed
16.
Zurück zum Zitat Vander, J. F., Morgan, C. M., & Schatz, H. (1989). Growth rate of subretinal neovascularization in age-related macular degeneration. Ophthalmology, 96(9), 1422–1426.CrossRefPubMed Vander, J. F., Morgan, C. M., & Schatz, H. (1989). Growth rate of subretinal neovascularization in age-related macular degeneration. Ophthalmology, 96(9), 1422–1426.CrossRefPubMed
17.
Zurück zum Zitat Muether, P. S., Hermann, M. M., Koch, K., & Fauser, S. (2011). Delay between medical indication to anti-VEGF treatment in age related macular degeneration can result in a loss of visual acuity. Graefe’s Archive for Clinical and Experimental Ophthalmology, 249(5), 633–637.CrossRefPubMed Muether, P. S., Hermann, M. M., Koch, K., & Fauser, S. (2011). Delay between medical indication to anti-VEGF treatment in age related macular degeneration can result in a loss of visual acuity. Graefe’s Archive for Clinical and Experimental Ophthalmology, 249(5), 633–637.CrossRefPubMed
18.
Zurück zum Zitat Rauch, R., Weingessel, B., Maca, S. M., & Vécsei-Marlovits, P. V. (2012). Time to first treatment—the significance of early treatment of exudative age related macular degeneration. Retina (Philadelphia, Pa.), 32(7), 1260–1264.CrossRef Rauch, R., Weingessel, B., Maca, S. M., & Vécsei-Marlovits, P. V. (2012). Time to first treatment—the significance of early treatment of exudative age related macular degeneration. Retina (Philadelphia, Pa.), 32(7), 1260–1264.CrossRef
19.
Zurück zum Zitat Weingessel, B., Hintermayer, G., Maca, S. M., Rauch, R., & Vecsei-Marlovits, P. V. (2012). The significance of early treatment of exudative age-related macular degeneration: 12 months’ results. Wiener Klinische Wochenschrift, 124(21–22), 750–755.CrossRefPubMed Weingessel, B., Hintermayer, G., Maca, S. M., Rauch, R., & Vecsei-Marlovits, P. V. (2012). The significance of early treatment of exudative age-related macular degeneration: 12 months’ results. Wiener Klinische Wochenschrift, 124(21–22), 750–755.CrossRefPubMed
20.
Zurück zum Zitat Finger, R. P., Guymer, R. H., Gillies, M. C., & Keeffe, J. E. (2014). The impact of anti-vascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration. Ophthalmology, 121(6), 1246–1251.CrossRefPubMed Finger, R. P., Guymer, R. H., Gillies, M. C., & Keeffe, J. E. (2014). The impact of anti-vascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration. Ophthalmology, 121(6), 1246–1251.CrossRefPubMed
21.
Zurück zum Zitat Submacular Surgery Trials (SST) Research Group (2007). Evaluation of minimum clinically meaningful changes in scores on the National Eye Institute Visual Function Questionnaire (NEI-VFQ). SST report number 19. Ophthalmic Epidemiology, 14(4), 205–215.CrossRef Submacular Surgery Trials (SST) Research Group (2007). Evaluation of minimum clinically meaningful changes in scores on the National Eye Institute Visual Function Questionnaire (NEI-VFQ). SST report number 19. Ophthalmic Epidemiology, 14(4), 205–215.CrossRef
22.
Zurück zum Zitat Dong, L.M., Childs, A.L., Mangione, C.M., Bass, E.B., Bressler, N.M., Hawkins, B.S., Marsh, M.J., Miskala, P., Jaffee, H.A., McCaffrey, L.A., & Submacular Surgery Trials Research Group. (2004). Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4. American Journal of Ophthalmology. 138(1), 91–108.CrossRefPubMed Dong, L.M., Childs, A.L., Mangione, C.M., Bass, E.B., Bressler, N.M., Hawkins, B.S., Marsh, M.J., Miskala, P., Jaffee, H.A., McCaffrey, L.A., & Submacular Surgery Trials Research Group. (2004). Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4. American Journal of Ophthalmology. 138(1), 91–108.CrossRefPubMed
23.
Zurück zum Zitat Submacular Surgery Trials (SST) Research Group (2004). Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: Quality-of-life findings. SST report no. 12. Ophthalmology, 111(11), 1981–1992.CrossRef Submacular Surgery Trials (SST) Research Group (2004). Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: Quality-of-life findings. SST report no. 12. Ophthalmology, 111(11), 1981–1992.CrossRef
24.
Zurück zum Zitat Submacular Surgery Trials (SST) Research Group (2004). Surgery for predominantly hemorrhagic choroidal neovascular lesions of age-related macular degeneration: Quality-of-life findings. SST report no. 14. Ophthalmology, 111(11), 2007–2014.CrossRef Submacular Surgery Trials (SST) Research Group (2004). Surgery for predominantly hemorrhagic choroidal neovascular lesions of age-related macular degeneration: Quality-of-life findings. SST report no. 14. Ophthalmology, 111(11), 2007–2014.CrossRef
26.
Zurück zum Zitat Submacular Surgery Trials. (1998). Manual of Procedures. Spring-field, VA: National Technical Information Service. NTIS Publication PB98-16648. Submacular Surgery Trials. (1998). Manual of Procedures. Spring-field, VA: National Technical Information Service. NTIS Publication PB98-16648.
27.
Zurück zum Zitat Submacular Surgery Trials (SST) Research Group (2004). Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings. SST report no. 11. Ophthalmology, 111(11), 1967–1980.CrossRef Submacular Surgery Trials (SST) Research Group (2004). Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings. SST report no. 11. Ophthalmology, 111(11), 1967–1980.CrossRef
28.
Zurück zum Zitat Mangione, C. M., Berry, S., Spritzer, K., Janz, N. K., Klein, R., Owsley, C., et al. (1998). Identifying the content area for the National Eye Institute Vision Function Questionnaire (NEI-VFQ): results from focus groups with visually impaired persons. Archives of Ophthalmology, 116(2), 227–233.CrossRefPubMed Mangione, C. M., Berry, S., Spritzer, K., Janz, N. K., Klein, R., Owsley, C., et al. (1998). Identifying the content area for the National Eye Institute Vision Function Questionnaire (NEI-VFQ): results from focus groups with visually impaired persons. Archives of Ophthalmology, 116(2), 227–233.CrossRefPubMed
30.
Zurück zum Zitat Ware, Jr, J. E., & Sherbourne, C. D. (1992). The MOS 36-Item Short-Form Health Survey (SF-36), I. Conceptual framework and item selection. Medical Care, 30(6), 473–483.CrossRefPubMed Ware, Jr, J. E., & Sherbourne, C. D. (1992). The MOS 36-Item Short-Form Health Survey (SF-36), I. Conceptual framework and item selection. Medical Care, 30(6), 473–483.CrossRefPubMed
32.
Zurück zum Zitat Zigmond, A. S., & Snaith, R. P. (1983). The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica, 67(6), 361–370.CrossRefPubMed Zigmond, A. S., & Snaith, R. P. (1983). The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica, 67(6), 361–370.CrossRefPubMed
33.
Zurück zum Zitat Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002). The validity of the hospital anxiety and depression scale. An updated literature review. Journal of Psychosomatic Research, 52(2), 69–77.CrossRefPubMed Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002). The validity of the hospital anxiety and depression scale. An updated literature review. Journal of Psychosomatic Research, 52(2), 69–77.CrossRefPubMed
34.
Zurück zum Zitat Mangione, C.M., Lee, P.P., Gutierrez, P.R., Spritzer, K., Berry, S., Hays, R.D., National Eye Institute Visual Function Questionnaire Field Test Investigators. (2001). Development of the 25-item National Eye Institute Visual Function Questionnaire. Archives of Ophthalmology, 119(7), 1050–1058.CrossRefPubMed Mangione, C.M., Lee, P.P., Gutierrez, P.R., Spritzer, K., Berry, S., Hays, R.D., National Eye Institute Visual Function Questionnaire Field Test Investigators. (2001). Development of the 25-item National Eye Institute Visual Function Questionnaire. Archives of Ophthalmology, 119(7), 1050–1058.CrossRefPubMed
35.
Zurück zum Zitat Submacular Surgery Trials Research Group (2003). Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: Findings in patients with subfoveal choroidal neovascularization–SST Report No. 1. Archives of Ophthalmology, 121(4), 531–539.CrossRef Submacular Surgery Trials Research Group (2003). Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: Findings in patients with subfoveal choroidal neovascularization–SST Report No. 1. Archives of Ophthalmology, 121(4), 531–539.CrossRef
36.
Zurück zum Zitat Likert, R. (1932). A Technique for the measurement of attitudes. Archives of Psychology, 140, 1–55. Likert, R. (1932). A Technique for the measurement of attitudes. Archives of Psychology, 140, 1–55.
37.
Zurück zum Zitat Submacular Surgery Trials (SST) Research Group (2007). Incident choroidal neovascularization in fellow eyes of patients with unilateral subfoveal choroidal neovascularization secondary to age-related macular degeneration: SST report No. 20 from the Submacular Surgery Trials Research Group. Archives of Ophthalmology, 125(10), 1323–1330.CrossRef Submacular Surgery Trials (SST) Research Group (2007). Incident choroidal neovascularization in fellow eyes of patients with unilateral subfoveal choroidal neovascularization secondary to age-related macular degeneration: SST report No. 20 from the Submacular Surgery Trials Research Group. Archives of Ophthalmology, 125(10), 1323–1330.CrossRef
38.
Zurück zum Zitat Miskala, P. H., Bressler, N. M., & Meinert, C. L. (2004). Relative contributions of reduced vision and general health to NEI-VFQ scores in patients with neovascular age-related macular degeneration. Archives of Ophthalmology, 122(5), 758–766.CrossRefPubMed Miskala, P. H., Bressler, N. M., & Meinert, C. L. (2004). Relative contributions of reduced vision and general health to NEI-VFQ scores in patients with neovascular age-related macular degeneration. Archives of Ophthalmology, 122(5), 758–766.CrossRefPubMed
39.
Zurück zum Zitat Miskala, P. H., Bressler, N. M., & Meinert, C. L. (2004). Is adjustment of National Eye Institute Visual Function Questionnaire scores for general health necessary in randomized trials? American Journal of Ophthalmology, 137(5), 961–963.CrossRefPubMed Miskala, P. H., Bressler, N. M., & Meinert, C. L. (2004). Is adjustment of National Eye Institute Visual Function Questionnaire scores for general health necessary in randomized trials? American Journal of Ophthalmology, 137(5), 961–963.CrossRefPubMed
40.
Zurück zum Zitat Macular Photocoagulation Study Group (1993). Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Archives of Ophthalmology, 111(9), 1189–1199.CrossRef Macular Photocoagulation Study Group (1993). Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Archives of Ophthalmology, 111(9), 1189–1199.CrossRef
41.
Zurück zum Zitat Macular Photocoagulation Study Group (1997). Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Archives of Ophthalmology, 115(6), 741–747.CrossRef Macular Photocoagulation Study Group (1997). Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Archives of Ophthalmology, 115(6), 741–747.CrossRef
42.
Zurück zum Zitat Massof, R. W., & Ahmadian, L. (2007). What do different visual function questionnaires measure? Ophthalmic Epidemiology, 14(4), 198–204.CrossRefPubMed Massof, R. W., & Ahmadian, L. (2007). What do different visual function questionnaires measure? Ophthalmic Epidemiology, 14(4), 198–204.CrossRefPubMed
43.
Zurück zum Zitat Lindblad, A. S., & Clemons, T. E. (2005). Responsiveness of the National Eye Institute Visual Function Questionnaire to progression to advanced age-related macular degeneration, vision loss, and lens opacity: AREDS Report No. 14. Archives of Ophthalmology, 123(9), 1207–1214.CrossRefPubMed Lindblad, A. S., & Clemons, T. E. (2005). Responsiveness of the National Eye Institute Visual Function Questionnaire to progression to advanced age-related macular degeneration, vision loss, and lens opacity: AREDS Report No. 14. Archives of Ophthalmology, 123(9), 1207–1214.CrossRefPubMed
44.
Zurück zum Zitat Rosenfeld, P.J., Brown, D.M., Heier, J.S., Boyer, D.S., Kaiser, P.K., Chung, C.Y., Kim, R.Y., MARINA Study Group. (2006). Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine. 355(14):1419–1431.CrossRefPubMed Rosenfeld, P.J., Brown, D.M., Heier, J.S., Boyer, D.S., Kaiser, P.K., Chung, C.Y., Kim, R.Y., MARINA Study Group. (2006). Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine. 355(14):1419–1431.CrossRefPubMed
Metadaten
Titel
Visual function quality of life measure changes upon conversion to neovascular age-related macular degeneration in second eyes
verfasst von
Yannis M. Paulus
Joan L. Jefferys
Barbara S. Hawkins
Adrienne W. Scott
Publikationsdatum
29.03.2017
Verlag
Springer International Publishing
Erschienen in
Quality of Life Research / Ausgabe 8/2017
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-017-1547-z

Weitere Artikel der Ausgabe 8/2017

Quality of Life Research 8/2017 Zur Ausgabe